Quote | LAVA Therapeutics N.V. (NASDAQ:LVTX)
Last: | $2.06 |
---|---|
Change Percent: | 1.69% |
Open: | $2.04 |
Close: | $2.06 |
High: | $2.1299 |
Low: | $2.01 |
Volume: | 33,629 |
Last Trade Date Time: | 07/19/2024 03:00:00 am |
News | LAVA Therapeutics N.V. (NASDAQ:LVTX)
UTRECHT, The Netherlands and PHILADELPHIA, June 20, 2024 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (NASDAQ: LVTX, “LAVA”), a clinical-stage immuno-oncology company focused on developing its proprietary Gammabody ® platform of bispecific gamma delta T cell eng...
UTRECHT, The Netherlands and PHILADELPHIA, May 30, 2024 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (NASDAQ: LVTX, “LAVA,” or “Company”), a clinical-stage immuno-oncology company focused on developing its proprietary Gammabody® platform of bispecific gamm...
Message Board Posts | LAVA Therapeutics N.V. (NASDAQ:LVTX)
Subject | By | Source | When |
---|---|---|---|
Always dumping even with good news. MYbe someday | heyitsmeagain | investorshub | 04/17/2023 6:45:14 PM |
The company is dumping shares on the bid. | Pedro2004 | investorshub | 09/27/2022 1:45:20 PM |
Huge run-up of 99% at one point it | subslover | investorshub | 09/26/2022 11:33:05 PM |
I've been waiting for this to break, all | Pedro2004 | investorshub | 09/26/2022 7:27:35 PM |
Seagen and LAVA Therapeutics Announce Exclusive Worldwide License | subslover | investorshub | 09/26/2022 12:26:34 PM |
News, Short Squeeze, Breakout and More Instantly...
LAVA Therapeutics N.V. Company Name:
LVTX Stock Symbol:
NASDAQ Market:
LAVA Therapeutics N.V. Website:
UTRECHT, The Netherlands and PHILADELPHIA, June 20, 2024 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (NASDAQ: LVTX, “LAVA”), a clinical-stage immuno-oncology company focused on developing its proprietary Gammabody ® platform of bispecific gamma delta T cell eng...
UTRECHT, The Netherlands and PHILADELPHIA, May 30, 2024 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (NASDAQ: LVTX, “LAVA,” or “Company”), a clinical-stage immuno-oncology company focused on developing its proprietary Gammabody® platform of bispecific gamm...
LAVA-1207 dose escalation progressing in Phase 1/2a trial in prostate cancer, with pembrolizumab combination expected to begin in Q2 2024 Received $7.0 million clinical development milestone from Pfizer for PF-08046052 (formerly LAVA-1223) in Phase 1 LAVA-1266 on track for Q2 2024 IND sub...